48 of 500
Pfizer
Pfizer
48
Financials: Latest Results
Rank: 48
Previous rank: 40
CEO: Ian C. Read

Pharmaceutical giant Pfizer spent much of 2012 still reeling from the aftermath of losing exclusivity of the cholesterol-lowering medication Lipitor in November 2011. In his annual letter to shareholders, Chairman and CEO Ian Read attributed the record operational loss of $7.4 billion to the patent expirations of popular drugs like Lipitor. By the end of the fourth quarter, the company reported a $1.8 billion (or 33%) loss in primary care revenues due to patent expirations. The blow was somewhat softened by the success of drugs like Lyrica, Celebrex and Viagra, bringing the primary care unit revenues to only a slightly better 28% decrease in the fourth quarter compared to the same time in 2011. But it hasn't been all bad news for Pfizer. The company continued to re-structure its business strategy with the sale of its nutrition unit to Nestle and the recent IPO of the company's stand-alone animal health business, Zoetis.

Headquarters:
235 E. 42nd St.
New York, NY. 10017
212-733-2323
Website: www.pfizer.com
Network with Pfizer
Key financials
$ millions
% change from 2011
Revenues
61,244
-9.8
Profits
14,570
45.6
Assets
185,798
Stockholder's equity
81,260
Market cap (on 3/29/2013)
207,476.3
Profits as % of
Revenues
23.8
Assets
7.8
Stockholders' equity
17.9
Earnings per share
2012$
1.94
% change from 2011
52.8
2002-2012 annual growth rate %
2.9
Total return to investors
%
2012
20.4
2002-2012 annual rate
2
From the May 20, 2013 issue

Notes:
Includes revenues from discontinued operations.
What do you think of Pfizer?
Companies are ranked by total revenues for their respective fiscal years. Included in the survey are companies that are incorporated in the U.S. and operate in the U.S. and file financial statements with a government agency. More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.